We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Nathan Fowler

Nathan H Fowler MD

Professor of Medicine, Department of Lymphoma and Myeloma, Division of Cancer Medicine, University of Texas MD Anderson Cancer Center, Houston, TX
Nathan H Fowler, MD, is a Professor of Medicine in the Department of Lymphoma and Myeloma, Division of Cancer Medicine, at the University of Texas MD Anderson Cancer Center in Houston, Texas. He received his MD and completed his residency at the University of Texas before completing a clinical fellowship in hematology/oncology at Georgetown University where he was a chief fellow. Dr Fowler's interest in immunomodulatory agents began during his hematology/oncology fellowship at George University Hospital, where he helped develop some of the first protocols to use lenalidomide in chronic lymphocytic leukemia (CLL). His focus at MD Anderson has been the further development of novel therapeutic regimens with immunomodulatory therapies to help patients with low-grade non-Hodgkin lymphoma. Dr Fowler also serves as the chairman of several Phase I and investigator-initiated Phase II trials for patients with non-Hodgkin lymphoma.